In the News

Pregnancy after breast cancer does not increase chance of recurrence

Al Saint Jacques, MDLinx | June 16, 2017

Investigators reported that women who became pregnant after an early breast cancer diagnosis, including those who were diagnosed with estrogen receptor (ER)-positive tumors, did not have a higher incidence of cancer recurrence and death than those who did not become pregnant. These findings, which were from a retrospective study of 1,200 women, provide reassurance to breast cancer survivors who are contemplating pregnancy, according to a study presented in Chicago, IL, in early June at the American Society of Clinical Oncology 2017 Annual Meeting.

Pregnancy after early breast cancer

No higher incidence of cancer recurrence or death was found compared to those who did not become pregnant.

Research shows that breast cancer is the most common cancer in women of reproductive age. Breast cancer in young women may occur before the completion of reproductive plans, considering current trends toward delaying childbearing. Although half of young women with newly diagnosed breast cancer report interest in having children, less than 10% become pregnant after treatment.¹ In fact, of all cancer survivors, breast cancer survivors are the least likely to have a baby after diagnosis.

Physicians and patients have long been concerned that pregnancy might increase the possibility of breast cancer recurrence, particularly for women with ER-positive disease. Because ER-positive breast cancer is fueled by estrogen, the fear is that hormone levels during pregnancy could coax any occult cancer cells – those that may remain in the body after treatment – to grow.

The need to interrupt adjuvant (post-surgery) hormone therapy before trying to achieve a pregnancy is another concern regarding pregnancy in women with ER-positive cancer. Such hormone therapy helps prevent cancer recurrence, and it is recommended that women receive it for at least 5 years and in some cases up to 10 years.

“Our findings confirm that pregnancy after breast cancer should not be discouraged, even for women with ER-positive cancer,” said lead study author Matteo Lambertini, MD, a medical oncologist and ESMO fellow at the Institut Jules Bordet in Brussels, Belgium. “However, when deciding how long to wait before becoming pregnant, patients and doctors should consider each woman’s personal risk for recurrence, particularly for women who need adjuvant hormone therapy.”

With a total enrollment of 1,207 patients, this is the largest study to investigate the safety of pregnancy after breast cancer and the only study to address this question specifically in women with ER-positive breast cancer, according to study authors.

This study included women who were diagnosed with non-metastatic breast cancer before 2008, under the age of 50. The majority (57%) had ER-positive cancer, and more than 40% had poor prognostic factors, such as large tumor size and cancer spread to the axillary lymph nodes. Among the 1,207 patients in the study, 333 of the women became pregnant, and 874 did not. Study authors noted that as per the case-control study design, researchers matched each patient who became pregnant with three patients who had similar cancer characteristics but did not become pregnant.

The median time from diagnosis to conception was 2.4 years. Women with ER-positive breast cancer tended to achieve pregnancy later than those with ER-negative disease. In addition, 23% of patients with ER-positive disease had a pregnancy beyond 5 years from diagnosis as compared with 7% in those with ER-negative tumors.

After a median follow-up of about 10 years from cancer diagnosis, there was no difference found in disease-free survival between women who became pregnant and those who did not, irrespective of ER status. Secondary analyses demonstrated that there was no difference in disease-free survival compared with women who did not become pregnant, irrespective of whether women completed the pregnancy or had an abortion, became pregnant less than two years or more than two years from breast cancer diagnosis, and whether patients had breastfed.

Among survivors of ER-positive cancer, there was also no difference found in overall survival between women who became pregnant and those who did not. Survivors of ER-negative breast cancer who became pregnant were found to have a 42% lower chance of dying than those who did not become pregnant.

“It’s possible that pregnancy could be a protective factor for patients with ER-negative breast cancer, through either immune system mechanisms or hormonal mechanisms, but we need more research into this,” said Dr. Lambertini.

Although there were limited data on breastfeeding in this study (64 patients, with 25 women who reported having breastfed their newborn), the results suggest that breastfeeding is feasible, even after breast surgery.

Although it was large, this study had limited information on the use of assisted reproductive technologies (such as in vitro fertilization) in breast cancer survivors, and HER2 status was unknown for about 80% of the women. Additional research is also needed to study the effect of pregnancy on health outcomes of women with BRCA mutations, a group that generally develops breast cancer at a younger age.

Researchers noted that a large clinical trial (the POSITIVE study) is under way investigating the impact of interrupting adjuvant hormone therapy to allow for pregnancy in women with ER-positive breast cancer. This study will also provide additional insights on the impact of reproductive technologies and breastfeeding.

ASCO Perspective:

“These data provide reassurance to breast cancer survivors that having a baby after a breast cancer diagnosis may not increase the chance of their cancer coming back. For many young women around the world who want to grow and expand their families, it’s very comforting news,” said Erica L. Mayer, MD, MPH, ASCO Expert.

This study was partly supported by grants from Les Amis de l’Institut Bordet (grant number 2012-09) and the European School of Oncology (ESO). The International Breast Cancer Study Group (IBCSG) study, which provided patient information for this study, was partially funded by the National Institutes of Health (grant number CA-753562).

Reference

1. Letourneau JM, et al. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2012;118(6):1710-1717.